{"title":"[肺炎学：2024年的新动向]。","authors":"Frédéric Lador, Pieter-Jan Gijs, Léon Genecand, Radhika Sood, Caroline Rayroux, Romain Messe, Ivan Guerreiro, John-David Aubert","doi":"10.53738/REVMED.2025.21.900-1.67","DOIUrl":null,"url":null,"abstract":"<p><p>In 2024, several important innovations have enriched the management of respiratory diseases, including pulmonary hypertension, tuberculosis, COPD, and obstructive sleep apnea syndrome (OSAS). Notable advancements include the introduction of sotatercept in Switzerland for pulmonary arterial hypertension and mediastinal cryobiopsies, reflecting a shift toward more personalized medicine. Meanwhile, biologic therapies for COPD offer promising perspectives, and a potential path is emerging for shortening the treatment of certain forms of tuberculosis. These developments open the door to new therapeutic options, with the hope of enhancing care and delivering meaningful clinical benefits to patients.</p>","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"21 900-1","pages":"67-72"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Pneumology : what's new in 2024].\",\"authors\":\"Frédéric Lador, Pieter-Jan Gijs, Léon Genecand, Radhika Sood, Caroline Rayroux, Romain Messe, Ivan Guerreiro, John-David Aubert\",\"doi\":\"10.53738/REVMED.2025.21.900-1.67\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In 2024, several important innovations have enriched the management of respiratory diseases, including pulmonary hypertension, tuberculosis, COPD, and obstructive sleep apnea syndrome (OSAS). Notable advancements include the introduction of sotatercept in Switzerland for pulmonary arterial hypertension and mediastinal cryobiopsies, reflecting a shift toward more personalized medicine. Meanwhile, biologic therapies for COPD offer promising perspectives, and a potential path is emerging for shortening the treatment of certain forms of tuberculosis. These developments open the door to new therapeutic options, with the hope of enhancing care and delivering meaningful clinical benefits to patients.</p>\",\"PeriodicalId\":21286,\"journal\":{\"name\":\"Revue medicale suisse\",\"volume\":\"21 900-1\",\"pages\":\"67-72\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue medicale suisse\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53738/REVMED.2025.21.900-1.67\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue medicale suisse","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53738/REVMED.2025.21.900-1.67","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
In 2024, several important innovations have enriched the management of respiratory diseases, including pulmonary hypertension, tuberculosis, COPD, and obstructive sleep apnea syndrome (OSAS). Notable advancements include the introduction of sotatercept in Switzerland for pulmonary arterial hypertension and mediastinal cryobiopsies, reflecting a shift toward more personalized medicine. Meanwhile, biologic therapies for COPD offer promising perspectives, and a potential path is emerging for shortening the treatment of certain forms of tuberculosis. These developments open the door to new therapeutic options, with the hope of enhancing care and delivering meaningful clinical benefits to patients.
期刊介绍：
Destinée aux professionnels de santé, la plateforme revmed.ch regroupe la version électronique de la Revue Médicale Suisse et les applications de formation et d"aide à la prise de décision eRMS. La eRMS est le fruit d’une large collaboration entre institutions et praticiens de Suisse romande.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
